Desvenlafaxine - extended release - Alembic

Drug Profile

Desvenlafaxine - extended release - Alembic

Latest Information Update: 07 Apr 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alembic
  • Developer Sun Pharmaceutical Industries
  • Class Antidepressants; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder

Most Recent Events

  • 25 Mar 2015 Sun Pharmaceutical Industries acquires Ranbaxy
  • 08 May 2013 Launched for Major depressive disorder in USA (PO)
  • 05 Mar 2013 Registered for Major depressive disorder in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top